XML 33 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Data (Tables)
 9 Months Ended
Jun. 30, 2018
Segment Reporting [Abstract]  
Financial Information for Company's Segments
Financial information for the Company’s segments was as follows:
 
Three Months Ended
June 30,
 
Nine Months Ended
June 30,
(Millions of dollars)
2018
 
2017
 
2018
 
2017
Revenues (a)
 
 
 
 
 
 
 
Medical (b)
$
2,246

 
$
1,871

  
$
6,270

 
$
5,477

Life Sciences
1,079

 
997

  
3,222

 
2,937

Interventional (b)
954

 
167

 
2,089

 
513

Total Revenues
$
4,278

 
$
3,035

 
$
11,581

 
$
8,927

Income (Loss) Before Income Taxes
 
 
 
 
 
 
 
Medical (b) (c)
$
732

 
$
491

 
$
1,943

 
$
1,451

Life Sciences (d)
241

 
199

  
893

 
574

Interventional (b) (c)
175

 
61

 
102

 
187

Total Segment Operating Income
1,148

 
751

  
2,938

 
2,212

Acquisitions and other restructurings
(146
)
 
(81
)
 
(604
)
 
(243
)
Net interest expense
(174
)
 
(165
)
 
(470
)
 
(334
)
Other unallocated items (e)
(180
)
 
(909
)
 
(1,106
)
 
(985
)
Income (Loss) Before Income Taxes
$
647

 
$
(404
)
 
$
759

 
$
650

(a)
The Company has no material intersegment revenues.
(b)
Prior-year amounts have been reclassified to reflect the movement of certain product offerings previously reported in the Medical segment and which are now reported in the Interventional segment, as further discussed above. Revenues associated with these products were $167 million and $513 million in the three and nine month-periods ended June 30, 2017, respectively. Segment operating income associated with these products were $61 million and $187 million in the three and nine month-periods ended June 30, 2017, respectively.
(c)
The amounts in 2018 included expense related to the recognition of a $478 million fair value step-up adjustment related to Bard's inventory on the acquisition date. The step-up adjustments recognized by the Medical and Interventional segments for the three months ended June 30, 2018 were $7 million and $49 million, respectively, and the adjustments recognized by the Medical and Interventional segments for the nine months ended June 30, 2018 were $60 million and $418 million, respectively.
(d)
The amounts in 2018 included charges recorded to write down the carrying value of certain intangible and other assets in the Biosciences unit.
(e)
Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amounts for the three and nine months ended June 30, 2017 also included a $741 million non-cash charge resulting from a modification to the Company's dispensing equipment lease contracts with customers. The amount for the nine months ended June 30, 2017 also included income resulting from the reversal of certain litigation reserves as further discussed in Note 5.

Revenues by Geographic Areas
Revenues by geographic areas were as follows:
 
Three Months Ended
June 30,
 
Nine Months Ended
June 30,
(Millions of dollars)
2018
 
2017
 
2018
 
2017
Revenues
 
 
 
 
 
 
 
United States
$
2,338

 
$
1,603

 
$
6,319

 
$
4,859

International
1,941

 
1,433

 
5,261

 
4,068

Total Revenues
$
4,278

 
$
3,035

 
$
11,581

 
$
8,927